Related Experiment Video
Updated: Jan 29, 2026

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
JAK inhibitors for alopecia areata: a systematic review and meta-analysis
K Phan1,2, D F Sebaratnam1,2,3
1Department of Dermatology, Liverpool Hospital, Sydney, NSW, Australia.
Abstract:
There have been a number of case reports and small clinical trials reporting promising outcomes of Janus Kinase (JAK) inhibitors tofacitinib, ruxolitinib and baricitinib for alopecia areata (AA). The majority of the literature to date is based on small volume data, with a lack of definitive evidence or guidelines. To determine the expected response of AA to JAK inhibitor therapy and factors which influence response and recurrence rates. A systematic review and meta-analysis was performed according to PRISMA guidelines. From 30 studies and 289 cases, there were 72.4% responders, good responders 45.7% and partial responders 21.4%. Mean time to initial hair growth was 2.2 ± 6.7 months, and time to complete hair regrowth was 6.7 ± 2.2 months. All 37 recurrences occurred when treatment was ceased after 2.7 months. Oral route was significantly associated with response to treatment compared to topical therapy. No difference was found between paediatric and adult cases in proportion of responses. There is promising low-quality evidence regarding the effectiveness of JAK inhibitors in AA. Future large-sized randomized studies are required to confirm findings.
Insights
Janus Kinase (JAK) inhibitors show promise for alopecia areata (AA) treatment, with over 70% of patients responding. Oral JAK inhibitors were more effective than topical treatments, but further research is needed.
Area of Science:
- Dermatology
- Pharmacology
- Immunology
Background:
- Alopecia areata (AA) is an autoimmune condition with limited treatment options.
- Janus Kinase (JAK) inhibitors like tofacitinib, ruxolitinib, and baricitinib have shown potential in case reports and small trials for AA.
- Current literature lacks definitive evidence and guidelines on JAK inhibitor efficacy for AA.
Purpose of the Study:
- To determine the response rates of alopecia areata (AA) to Janus Kinase (JAK) inhibitor therapy.
- To identify factors influencing treatment response and recurrence rates in AA patients treated with JAK inhibitors.
- To synthesize existing evidence on JAK inhibitor effectiveness for AA.
Main Methods:
- A systematic review and meta-analysis were conducted following PRISMA guidelines.
- Data from 30 studies encompassing 289 cases of alopecia areata treated with JAK inhibitors were analyzed.
- Outcomes assessed included response rates, time to hair regrowth, and recurrence following treatment cessation.
Main Results:
- Overall response rate to JAK inhibitors was 72.4%, with 45.7% good responders and 21.4% partial responders.
- Mean time to initial hair growth was 2.2 months and complete regrowth was 6.7 months.
- Oral JAK inhibitor administration was significantly associated with better treatment response compared to topical routes. Recurrences (37 cases) occurred after treatment cessation.
Conclusions:
- Low-quality evidence suggests JAK inhibitors are promising for alopecia areata treatment.
- Oral JAK inhibitors appear more effective than topical formulations.
- Further large-scale randomized controlled trials are necessary to confirm these findings and establish treatment guidelines.
Related Concept Videos
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
The JAK-STAT Signaling Pathway
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Random and Systematic Errors
Directing Effect of Substituents: meta-Directing Groups

